Key statistics dashboard for Novocure Ltd (NVCR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Stock Data
| Price | $15.20 |
| Market Cap | $1.8B |
| Enterprise Value | $1.91B |
| Beta | 0.82 |
| Exchange | NASDAQ |
| Country | CH |
Valuation Multiples
| P/E Ratio | -11.49 |
| Price / Book | 5.13 |
| P/S | 2.49 |
| EV/EBITDA | -14.21 |
| EV/Sales | 2.73 |
| EV/FCF | -90.40 |
| P/FCF | -82.35 |
| Earnings Yield | -8.42% |
| FCF Yield | -1.19% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 76.13% |
| EBIT Margin | -21.30% |
| EBITDA Margin | -19.22% |
| Operating Margin | -22.08% |
| Net Margin | -21.25% |
| Return on Equity | -44.00% |
| Return on Assets | -18.68% |
| Return on Invested Capital | -26.15% |
| Return on Capital Employed | -26.88% |
Financial Health
| Current Ratio | 2.89 |
| Quick Ratio | 2.70 |
| Cash Ratio | 0.42 |
| Debt / Equity | 0.69 |
| Debt / Assets | 29.35% |
| Net Debt / EBITDA | -1.04 |
| Interest Coverage | -64.36 |
Per-Share Data
| Revenue per share | 6.03 |
| Book Value per share | 2.91 |
| Cash per share | 3.80 |
| FCF per share | -0.18 |
| Tangible Book Value per share | 2.91 |
| Dividend per share | 0.00 |
Related companies: AZTA · BLFS · ESTA · EVO · KMTS · NEOG · PLSE
Explore sector: Healthcare · Medical - Devices
More sections of NVCR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks